Sensitive versus standard estradiol: why the assay changes the answer

Two labs can measure the same blood and report estradiol numbers that are far apart, and neither is lying. The method is the difference, and most of the ranges quoted online do not say which one produced them.

What estradiol is, and why this population tests it

Estradiol is the principal estrogen in humans, and men make it too — mostly by aromatising testosterone, in adipose tissue, the liver, the brain and the gonads. It is not a contaminant of male physiology. It does load-bearing work in bone density, lipid handling, cognition and libido, which is why driving it to the floor causes problems of its own rather than solving anything.

Anyone on testosterone therapy has a reason to measure it: more substrate for aromatase means more estradiol, and the amount varies with dose, body composition and individual aromatase activity rather than following a fixed ratio. That is the practical case for measuring rather than guessing.

The assay problem, which is the whole point of this page

Direct estradiol immunoassays were developed and validated for the concentrations found in premenopausal women — hundreds of pg/mL. Men typically run in the tens. At that end of the scale the assay is being asked to work well below the range it was built for, and it does not: cross-reactivity with structurally similar steroids and metabolites inflates the reading, and the size of the error is not predictable per sample.¹

This is not a fringe position. The recommendation is that estradiol in men and children be measured by a sensitive LC-MS/MS-based method, and that people with low estradiol concentrations should not have it measured by immunoassay at all, because immunoassays overestimate at those concentrations and are unreliable there.¹ The Journal of Clinical Endocrinology and Metabolism went as far as requiring mass spectrometry for sex steroid measurements in the work it publishes.² A separate analysis in an epidemiological setting concluded that direct immunoassays lack the sensitivity and specificity to measure circulating estradiol validly in men or postmenopausal women.³

Established clinical use That the method matters at male concentrations is established, not a matter of opinion. What is not settled is what number you should be aiming at once you have a reliable one — see below.

What the three methods actually are

Standard immunoassay is the default on most general panels. Fast, cheap, validated for female concentrations, and the one to distrust in a male sample.

Sensitive or ultrasensitive usually means the lab has added an extraction or chromatographic step before the immunoassay, or is running a platform validated to a lower limit. Better at low concentrations than the standard assay, and what most TRT-oriented panels order.

LC/MS-MS — liquid chromatography with tandem mass spectrometry — separates estradiol from the things that confuse an antibody and then measures it by mass. It is the reference method, and "sensitive estradiol" is often, though not always, this.

TherapyLog stores which of these produced a value, because a trend that silently switches method is not a trend. If your report does not name the method, that is worth asking the lab about before reading much into the number.

Reading the number you have

The generic range in the fact box above is a male default and a fallback; the interval printed on your own report is better, because it belongs to the assay that produced your result. The optimal band the app shows is drawn from clinical literature and community practice for reading a trend and is non-diagnostic — being outside it is not itself a finding.

Off-label or community practice The commonly circulated targets for men on testosterone therapy — you will see 20–30 pg/mL quoted constantly — come from community practice and clinic convention rather than from a trial that established an optimal concentration. Worse, they are usually quoted with no method attached, which makes them close to meaningless: the same blood can read 45 on a standard immunoassay and 25 on LC/MS-MS. If you take a number off a forum, it is not usable unless you know which assay produced it.

The more defensible way to read estradiol is against your own symptoms and your own trend on a consistent assay, alongside total and free testosterone, rather than against a threshold quoted by a stranger.

What high and low estradiol are reported to feel like

Off-label or community practice These are the symptom patterns described in clinical practice and in the community, not diagnostic criteria — every one of them has other explanations, and several of them appear at both ends.

The reason both lists matter is that "crashed" estradiol is a real and avoidable iatrogenic problem. Aromatase inhibitors are potent, the dose–response in an individual is not predictable from the label, and joint pain, low mood, poor libido and — over time — bone density loss follow from suppressing estradiol too far. Treating a high number aggressively without symptoms is how people arrive at the opposite problem.

If you have symptoms at either end, the next step is a conversation with the clinician who prescribes for you, with a result from a method you can name in front of you. That is the whole of the advice this page will give about what to do.

What the app records for this marker

How the app adjusts this range by sex and age

Generated by running the app's own range function against each band, so this table cannot drift from what the app flags against. The optimal column is non-diagnostic throughout.

Compounds whose monitoring panel includes this marker

Generated by matching this marker's own aliases against the monitoring note on every compound in the app's reference, so the list is the app's, not an author's.

• Testosterone Cypionate Total T, Free T, E2 (sensitive assay), SHBG, Hematocrit, CBC, PSA, Lipids, CMP. Every 6-8 weeks adjusting; every 3-6 months stable.
• Progesterone Serum progesterone, estradiol, SHBG, breast exam, PAP smear. In men: testosterone, estradiol, comprehensive hormone panel.
• Kisspeptin-10 Total T, LH, FSH, E2 every 4 weeks. LH surge 30-60 min post-injection confirms receptor response.
• Anastrozole E2 sensitive assay, Total T, Free T every 6-8 weeks when adjusting.
• Tamoxifen Total T, LH, FSH, E2 at end of PCT. Goal: LH/FSH recovering, T returning toward baseline.
• Clomiphene LH, FSH, Total T, E2 throughout PCT and 4 weeks post-completion.
• HCG E2 (HCG aromatizes significantly), Total T. LH/FSH will be suppressed — this is expected.
• Enclomiphene Total T, Free T, LH, FSH, E2, Semen analysis (if fertility is goal), every 6-8 weeks when adjusting.
• Exemestane E2 sensitive assay, Total T, Free T, Lipid panel, Bone density with long-term use.
• Cabergoline Prolactin (primary target — keep in normal range), E2, Echocardiogram if using higher doses long-term.
• DHEA DHEA-S (primary marker), Total T, Free T, E2 (DHEA converts to both), PSA in men, lipid panel.
• Pregnenolone DHEA-S, testosterone, estradiol, progesterone, cortisol (AM fasted), comprehensive hormone panel at baseline and 8 weeks.
• Kisspeptin-54 LH, FSH, Total T, E2 every 4 weeks. LH surge 45-60 min post-injection confirms receptor response.
• Gonadorelin LH, FSH (will show some activity unlike HCG protocols), Total T, E2, testicular volume assessment. LH response 30-60 min post-injection confirms pituitary response.
• Testosterone Pellets Total T, Free T, E2, Hematocrit at 4 weeks post-insertion and at trough (just before next insertion). PSA annually. Insertion site monitoring for infection or extrusion.
• Estriol Estradiol (E2); Estriol (E3); Progesterone; FSH / LH; Bone density annually; Breast exam / mammogram
• Proviron Free Testosterone; SHBG; Estradiol (E2); Lipid panel; DHT
• Testosterone Propionate Total and Free Testosterone; Estradiol; Hematocrit; PSA men over 40; Lipid panel
• Raloxifene Breast tissue changes; Estradiol; Signs of clotting (calf pain, swelling); Liver function

Questions people actually ask

Is "sensitive estradiol" the same as LC/MS-MS?

Not always, and it is worth checking. Some labs use "sensitive" or "ultrasensitive" for a mass-spectrometry method; others use it for an immunoassay preceded by an extraction step. Both are more trustworthy than a standard direct immunoassay at male concentrations, but they are not identical, and switching between them mid-trend introduces a step change that is a method artefact rather than a physiological one.

My lab only offers the standard assay. Is the result useless?

Not useless, but treat it as an upper bound rather than a measurement, and do not compare it to a target quoted for a sensitive assay. If you can only get the standard assay, at least keep using the same one so the trend is internally consistent, and say which assay it was whenever you show the number to anyone.

Should I be taking an aromatase inhibitor for a high number?

This page will not answer that, and it is not evasion. Estradiol does necessary work, the symptom picture at both extremes overlaps, aromatase inhibitors are potent and easy to overshoot with, and a single number from an unnamed assay is thin ground for starting a drug. What the literature and community practice describe is treating symptoms rather than numbers, and confirming a high reading on a reliable assay first. The decision itself belongs to the clinician who prescribes for you.

Does the app convert pmol/L to pg/mL?

Yes — the converter above is the app's own function, and estradiol converts at 0.2724 from pmol/L to pg/mL. Non-US reports usually print pmol/L, which is one of the more common reasons a value looks alarming when it is ordinary.

Sources

Every claim above that is not a definition is either labelled by evidence tier or carries a numbered reference to one of these.

1. ADLM (formerly AACC), Optimal Testing: Estradiol Testing in Men Recommends LC/MS-based measurement in men and advises against immunoassay at low concentrations.
2. Handelsman & Wartofsky, Requirement for Mass Spectrometry Sex Steroid Assays, J Clin Endocrinol Metab 98(10):3971 (2013) The journal's editorial requiring mass spectrometry for sex steroid assays.
3. Limitations of Direct Immunoassays for Measuring Circulating Estradiol Levels in Postmenopausal Women and Men in Epidemiologic Studies, Cancer Epidemiol Biomarkers Prev 19(4):903 (2010) Direct immunoassays lack the sensitivity and specificity required at male and postmenopausal concentrations.